Cristiane H Squarize

Dr. Cristiane H Squarize

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in Cell Stem Cell
Verified
Journal Article
Closed access
RCRogerio Castilho
Rogerio Castilho
CSCristiane H Squarize
Cristiane H Squarize
LCLewis A. Chodosh
Lewis A. Chodosh
BWBart Williams
Bart Williams
JGJ.Silvio Gutkind
J.Silvio Gutkind

1 April 2009 in Oral Oncology
Verified
Journal Article
Closed access
AMAlfredo A. Molinolo
Alfredo A. Molinolo
PAPanomwat Amornphimoltham
Panomwat Amornphimoltham
CSCristiane H Squarize
Cristiane H Squarize
RCRogerio Castilho
Rogerio Castilho
VPVyomesh Patel
Vyomesh Patel
JGJ.Silvio Gutkind
J.Silvio Gutkind

13 May 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CSCristiane H Squarize
Cristiane H Squarize
RCRogerio Castilho
Rogerio Castilho
TBThomas H. Bugge
Thomas H. Bugge
JGJ.Silvio Gutkind
J.Silvio Gutkind
The management of slow or non-healing ulcerations constitutes an increasing clinical challenge in the developed world because of the ageing of the population and the pandemic rise in type II diabetes. Recent studies suggest that molecular circuitries deployed by tumor cells to promote cancerous growth may also contribute to tissue regeneration. Here, we exploited this emerging information to search for novel molecular targets to accelerate wound healing. We found that the activation of the PI3K-Akt-mTOR pathway, whose aberrant function is a frequent event in human neoplasia, represents an integral component of the normal wound healing process. By the use of genetically defined approaches, including the epithelial-specific ablation of Pten and Tsc1, we show that mTOR activation can dramatically increase epithelial cell proliferation, migration, and cutaneous wound healing, while pharmacological inhibition of mTOR with rapamycin delays wound closure. Overall, our findings indicate that the transient pharmacologic activation of the PI3K-Akt-mTOR signaling axis may represent a novel clinical intervention strategy to accelerate the healing of debilitating and life-threatening wounds.

2 October 2018 in Clinical Oral Implants Research
Verified
Journal Article
Closed access
PDF file
FSFernando Suarez
Fernando Suarez
CGCarlos Garaicoa
Carlos Garaicoa
TFTobias Fretwurst
Tobias Fretwurst
RCRogerio Castilho
Rogerio Castilho
CSCristiane H Squarize
Cristiane H Squarize

1 September 2006 in Neoplasia
Verified
Journal Article
Open access
CSCristiane H Squarize
Cristiane H Squarize
RCRogerio Castilho
Rogerio Castilho
VSVirote Sriuranpong
Virote Sriuranpong
DPDecio S. Pinto
Decio S. Pinto
JGJ.Silvio Gutkind
J.Silvio Gutkind
The development of head and neck squamous cell carcinoma (HNSCC) involves the accumulation of genetic and epigenetic alterations in tumor-suppressor proteins, together with the persistent activation of growth-promoting signaling pathways. The activation of epidermal growth factor receptor (EGFR) is a frequent event in HNSCC. However, EGFR-independent mechanisms also contribute to the activation of key intracellular signaling routes, including signal transducer and activator of transcription-3 (STAT3), nuclear factor kappaB (NFkappaB), and Akt. Indeed, the autocrine activation of the gp130 cytokine receptor in HNSCC cells by tumor-released cytokines, such as IL-6, can result in the EGFR-independent activation of STAT3. In this study, we explored the nature of the molecular mechanism underlying enhanced IL-6 secretion in HNSCC cells. We found that HNSCC cells display an increased activity of the IL-6 promoter, which is dependent on the presence of an intact NFkappaB site. Furthermore, NFkappaB inhibition downregulated IL-6 gene and protein expression, and decreased the release of multiple cytokines. Interestingly, interfering with NFkappaB function also prevented the autocrine/paracrine activation of STAT3 in HNSCC cells. These findings demonstrate a cross-talk between the NFkappaB and the STAT3 signaling systems, and support the emerging notion that HNSCC results from the aberrant activity of a signaling network.

Verified
Journal Article
Open access
PDF file
RCRogerio Castilho
Rogerio Castilho
CSCristiane H Squarize
Cristiane H Squarize
LALuciana Oliveira de Almeida
Luciana Oliveira de Almeida
Head and neck squamous carcinoma (HNSCC) is the sixth most prevalent cancer and one of the most aggressive malignancies worldwide. Despite continuous efforts to identify molecular markers for early detection, and to develop efficient treatments, the overall survival and prognosis of HNSCC patients remain poor. Accumulated scientific evidences suggest that epigenetic alterations, including DNA methylation, histone covalent modifications, chromatin remodeling and non-coding RNAs, are frequently involved in oral carcinogenesis, tumor progression, and resistance to therapy. Epigenetic alterations occur in an unsystematic manner or as part of the aberrant transcriptional machinery, which promotes selective advantage to the tumor cells. Epigenetic modifications also contribute to cellular plasticity during tumor progression and to the formation of cancer stem cells (CSCs), a small subset of tumor cells with self-renewal ability. CSCs are involved in the development of intrinsic or acquired therapy resistance, and tumor recurrences or relapse. Therefore, the understanding and characterization of epigenetic modifications associated with head and neck carcinogenesis, and the prospective identification of epigenetic markers associated with CSCs, hold the promise for novel therapeutic strategies to fight tumors. In this review, we focus on the current knowledge on epigenetic modifications observed in HNSCC and emerging Epi-drugs capable of sensitizing HNSCC to therapy.